Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Astellas Pharma Inc.

BerGenBio AS

Betta Pharmaceuticals Co. Ltd.

Chugai Pharmaceutical Co., Ltd.

Exelixis, Inc.

HEC Pharm Co., Ltd.

Ignyta, Inc.

Les Laboratoires Servier SAS

Mirati Therapeutics Inc.

NeoPharm Co., Ltd.

Oribase Pharma

SignalChem Lifesciences Corp

Tolero Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) Overview 9

Therapeutics Development 10

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Products under Development by Stage of Development 10

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Products under Development by Therapy Area 11

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Products under Development by Indication 12

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Products under Development by Companies 16

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Products under Development by Universities/Institutes 22

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Assessment 24

Assessment by Monotherapy/Combination Products 24

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 27

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Companies Involved in Therapeutics Development 29

Astellas Pharma Inc. 29

BerGenBio AS 30

Betta Pharmaceuticals Co. Ltd. 31

Chugai Pharmaceutical Co., Ltd. 32

Exelixis, Inc. 33

HEC Pharm Co., Ltd. 35

Ignyta, Inc. 36

Les Laboratoires Servier SAS 37

Mirati Therapeutics Inc. 38

NeoPharm Co., Ltd. 39

Oribase Pharma 40

SignalChem Lifesciences Corp 41

Tolero Pharmaceuticals, Inc. 42

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Drug Profiles 43

BGB-10C9 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

BGB-324 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

BPI-9016 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

cabozantinib s-malate - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CH-5451098 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

CT-053 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

CT-413 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

gilteritinib fumarate - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

glesatinib - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

MGCD-516 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Monoclonal Antibody 2 to Inhibit AXL Kinase for Oncology - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Monoclonal Antibody 3 to Inhibit AXL Kinase for Oncology - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

NPS-1034 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Q-701 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

RXDX-106 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

S-49076 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

SGI-7079 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

SLC-0211 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecules to Inhibit AXL, FLT3 and NTRK for Solid Tumors and Blood Cancer - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

TP-0903 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Dormant Projects 92

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Discontinued Products 94

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Featured News & Press Releases 95

Jun 07, 2016: BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 95

Jun 05, 2016: Mirati Therapeutics Provides Update On Glesatinib Program 96

Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO 97

Jun 05, 2016: Mirati Therapeutics Provides Update On Sitravatinib Program 99

May 23, 2016: Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma 100

May 19, 2016: Mirati Therapeutics To Present Abstracts On glesatinib At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting 101

May 19, 2016: Mirati Therapeutics To Present Abstracts On sitravatinib (MGCD516) At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting 102

May 19, 2016: Astellas Oncology Announces Data on gilteritinib to be Presented at 2016 ASCO Annual Meeting 102

Apr 26, 2016: Diplomat to Dispense CABOMETYX (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma 103

Apr 25, 2016: Exelixis Announces FDA Approval of CABOMETYX (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy 103

Apr 20, 2016: Exelixis Announces Presentation On Cabozantinib At 2016 ASCO Annual Meeting 104

Apr 18, 2016: BerGenBio presents new data demonstrating that BGB324 enhances checkpoint inhibitor blockade 106

Apr 18, 2016: Tolero Pharmaceuticals Presents Data Demonstrating AXL Inhibition Leads to a Reversal of a Mesenchymal Phenotype Sensitizing Cancer Cells to Targeted Agents and Immuno-Oncology Therapies 107

Apr 12, 2016: Rigel Announces Presentation on preclinical research project MerTK at Upcoming American Association of Cancer Research (AACR) Conference 108

Apr 12, 2016: Tolero Pharmaceuticals to Present Update on TP-0903 at the AACR Annual Meeting 2016 108

Appendix 109

Methodology 109

Coverage 109

Secondary Research 109

Primary Research 109

Expert Panel Validation 109

Contact Us 109

Disclaimer 110

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Development by Companies, H2 2016 (Contd..2) 19

Products under Development by Companies, H2 2016 (Contd..3) 20

Products under Development by Companies, H2 2016 (Contd..4) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Products under Investigation by Universities/Institutes, H2 2016 23

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Pipeline by Astellas Pharma Inc., H2 2016 29

Pipeline by BerGenBio AS, H2 2016 30

Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 31

Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 32

Pipeline by Exelixis, Inc., H2 2016 33

Pipeline by HEC Pharm Co., Ltd., H2 2016 35

Pipeline by Ignyta, Inc., H2 2016 36

Pipeline by Les Laboratoires Servier SAS, H2 2016 37

Pipeline by Mirati Therapeutics Inc., H2 2016 38

Pipeline by NeoPharm Co., Ltd., H2 2016 39

Pipeline by Oribase Pharma, H2 2016 40

Pipeline by SignalChem Lifesciences Corp, H2 2016 41

Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 42

Dormant Projects, H2 2016 92

Dormant Projects (Contd..1), H2 2016 93

Discontinued Products, H2 2016 94

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports